Investors

Mindset is developing next-generation psychedelic medicines and related manufacturing processes to help treat neuropsychiatric patients with unmet needs.

Advancing an IP portfolio of innovative new psychedelic medicines that leverage clinical research into classic psychedelic drugs:
Lead Compound MSP-1014 demonstrating superior preclinical characteristics in head-to-head comparison with psilocybin
4 patent-pending new drug families drawing on novel chemical structures;
Over 75 compounds synthesized with preclinical data demonstrating promising results; and
Synthesis process for psilocybin demonstrating clear benefits over known processes.

Download Presentation

Press Releases & News

Mindset Pharma Announces Appointment of Clinician Scientist, Dr. Ishrat Husain, to Scientific Advisory Board

July 20, 2021

Mindset Pharma Announces Additional Preclinical Results Suggesting Superior Efficacy and Improved Safety in Head-to-Head Comparison to Psilocybin for its First Lead Clinical Candidate, MSP-1014

July 7, 2021

Mindset and InterVivo Solutions Announce Availability of First Preclinical Psychedelic Benchmark Data from COPE Program

June 14, 2021

Canaccord Genuity's Growth Conference

August 10, 2021

Info

Analyst Coverage

Firm

Maxim Group LLC

Analyst

Jason McCarthy, Ph.D.

Mindset Pharma Inc. is followed by the analysts listed above. Please note that any opinions, estimates or forecasts regarding Mindset Pharma Inc.'s performance made by these analysts are theirs alone and do not represent opinions, forecasts or predictions of Mindset Pharma Inc. or its management. Mindset Pharma Inc. does not by its reference above or distribution imply its endorsement of or concurrence with such information, conclusions or recommendations.